659 related articles for article (PubMed ID: 22855103)
1. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
2. Current concepts in breast cancer chemoprevention.
Chlebowski RT
Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912
[TBL] [Abstract][Full Text] [Related]
3. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
Vogel VG
Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
[TBL] [Abstract][Full Text] [Related]
4. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
[TBL] [Abstract][Full Text] [Related]
5. Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
Gradishar W; Glusman J; Lu Y; Vogel C; Cohen FJ; Sledge GW
Cancer; 2000 May; 88(9):2047-53. PubMed ID: 10813716
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Mocellin S; Pilati P; Briarava M; Nitti D
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582062
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
[TBL] [Abstract][Full Text] [Related]
8. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
9. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601
[TBL] [Abstract][Full Text] [Related]
10. Exemestane for breast-cancer prevention in postmenopausal women.
Goss PE; Ingle JN; Alés-Martínez JE; Cheung AM; Chlebowski RT; Wactawski-Wende J; McTiernan A; Robbins J; Johnson KC; Martin LW; Winquist E; Sarto GE; Garber JE; Fabian CJ; Pujol P; Maunsell E; Farmer P; Gelmon KA; Tu D; Richardson H;
N Engl J Med; 2011 Jun; 364(25):2381-91. PubMed ID: 21639806
[TBL] [Abstract][Full Text] [Related]
11. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC; Kilburn LS; Snowdon CF; Paridaens R; Coleman RE; Jones SE; Jassem J; Van de Velde CJ; Delozier T; Alvarez I; Del Mastro L; Ortmann O; Diedrich K; Coates AS; Bajetta E; Holmberg SB; Dodwell D; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Forbes J; Castiglione M; Stuart N; Stewart A; Fallowfield LJ; Bertelli G; Hall E; Bogle RG; Carpentieri M; Colajori E; Subar M; Ireland E; Bliss JM;
Lancet; 2007 Feb; 369(9561):559-70. PubMed ID: 17307102
[TBL] [Abstract][Full Text] [Related]
12. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
13. Chemoprevention of breast cancer.
Thomsen A; Kolesar JM
Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
[TBL] [Abstract][Full Text] [Related]
15. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
[TBL] [Abstract][Full Text] [Related]
16. [Specific estrogen receptor modulators (SERMs)].
Trémollières F; Lopes P
Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
[TBL] [Abstract][Full Text] [Related]
17. Risk-benefit profiles of women using tamoxifen for chemoprevention.
Nichols HB; DeRoo LA; Scharf DR; Sandler DP
J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
[TBL] [Abstract][Full Text] [Related]
18. The breast cancer chemoprevention debate.
Schmidt C
J Natl Cancer Inst; 2011 Nov; 103(22):1646-7. PubMed ID: 22025628
[No Abstract] [Full Text] [Related]
19. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
[TBL] [Abstract][Full Text] [Related]
20. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Love RR; Hutson PR; Havighurst TC; Cleary JF
Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]